Conditions: Prostate Cancer
Keywords: Prostate Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 22
Healthy volunteers: no

Brief summary:
This is a clinical trial of orally administered Ruxolitinib (INCB018424) in patients whose disease has progressed following 1 prior chemotherapy regimen (not including anti-androgens or ketoconazole) for metastatic, androgen-independent prostate cancer.

Detailed description:

Arms:
arm 1: Participants received ruxolitinib 25 mg orally twice daily in 12-hour intervals for 21-day cycles for as long as the study medication was tolerated and provided clinical benefit.

Interventions: intervention 1: Ruxolitinib
Intervention descriptions: intervention 1: Ruxolitinib 25 mg tablets taken with water twice a day.

Protocol document: